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Diabetic nephropathy (DN) is a long-term complication of diabetes mellitus that leads to end-stage renal disease. Microalbumin-
uria is used for the early detection of diabetic renal damage, but such levels do not reﬂect the state of incipient DN precisely in type
2 diabetic patients because microalbuminuria develops in other diseases, necessitating more accurate biomarkers that detect inci-
pient DN. Isobaric tags for relative and absolute quantiﬁcation (iTRAQ) were used to identify urinary proteins that were diﬀeren-
tially excreted in normoalbuminuric and microalbuminuric patients with type 2 diabetes where 710 and 196 proteins were identi-
ﬁed and quantiﬁed, respectively. Some candidates were conﬁrmed by 2-DE analysis, or validated by Western blot and multiple
reaction monitoring (MRM). Speciﬁcally, some diﬀerentially expressed proteins were veriﬁed by MRM in urine from normoalbu-
minuric and microalbuminuric patients with type 2 diabetes, wherein alpha-1-antitrypsin, alpha-1-acid glycoprotein 1, and pros-
tate stem cell antigen had excellent AUC values (0.849, 0.873, and 0.825, resp.). Moreover, we performed a multiplex assay using
thesebiomarkercandidates,resultinginamergedAUCvalueof0.921.AlthoughthediﬀerentiallyexpressedproteinsinthisiTRAQ
study require further validation in larger and categorized sample groups, they constitute baseline data on preliminary biomarker
candidates that can be used to discover novel biomarkers for incipient DN.
1.Introduction
Diabetes mellitus is a chronic disease with potentially devas-
tating complications. For example, diabetes mellitus is asso-
ciated with macrovascular complications, such as cardiovas-
cular and cerebrovascular diseases, and microvascular com-
plications, including diabetic nephropathy (DN) and retino-
pathy [1]. DN is a long-term complication of diabetes that is
causedbyspeciﬁcrenalstructuralalterations,suchasmesan-
gium expansion due to the progressive accumulation of
extracellular matrix (ECM), and by functional losses, such
as elevated glomerular basement membrane (GBM) perme-
ability [2].
DN occurs in 15% to 25% of type 1 diabetic patients and
30% to 40% of type 2 diabetic patients [3] and accounts for
approximately one-half of all new cases of end-stage renal
disease (ESRD). Furthermore, ESRD has a 5-year survival
rate of only 21% [4]. Because the progression of ESRD in
DN is irreversible, the early diagnosis of DN is necessary to
preventordelayprogressiontoESRD[5].Microalbuminuria
represents a potentially reversible incipient stage of neph-
ropathy and is used as a noninvasive index for the detection
of diabetic renal disease. Microalbuminuria is deﬁned as a
state in which abnormal amounts of albumin are excreted
in urine (30–300mg/24h versus <30mg/24h in normoalbu-
minuria) [5, 6].2 Experimental Diabetes Research
The use of microalbuminuria to predict incipient DN,
particularly in type 2 diabetic patients, is limited for several
reasons [7]: the microalbuminuric state also predicts cardio-
vascular disease in diabetic and nondiabetic individuals [8,
9], and it is associated with inﬂammation and hypertension
[5]. Consequently, the likelihood of detecting nondiabetic
renal disease or normal glomerular structure is observed
with microalbuminuria patients [10]. Thus, more accurate
biomarkers for incipient DN in type 2 diabetic patients are
required that can diﬀerentiate incipient DN from other con-
ditions in microalbuminuria patients, including cardiovas-
cular disease, inﬂammation, and hypertension.
Recently, to compare DN patients with non-DN patients,
proteomic technologies have been developed to identify uri-
nary marker candidates that are associated with the develop-
ment of DN. Various proteomic approaches have been used
for this purpose, including 2-DE, 2-DE DIGE, and SELDI-
TOF [5,11,12].However,becausemanystudieshavefocused
on restricted sets of targeted proteins, alterations in compre-
hensive urinary protein proﬁles in type 2 diabetes have not
been monitored. In particular, SELDI-TOF has been shown
to be a valuable technology for urinary proteomic analysis,
but the absolute identiﬁcation of diﬀerentially excreted pro-
teins remains challenging [13].
To scan a comprehensive diﬀerential proteome for pre-
liminaryDNcandidatebiomarkers,weuseda4-plexisobaric
tag for relative and absolute quantiﬁcation (iTRAQ, 4-plex),
allowing us to identify and quantify proteins in up to 4 sam-
ples [14]. The advantages of iTRAQ include whole labeling
of representative or pooled samples, comparatively high
throughput, and retention of posttranslational modiﬁcation
(PTM) data; one of its shortcomings is that it cannot be ap-
plied easily to a large collection of individual clinical samples
duetoreagentcostandtherequiredmassspectrometryeﬀort
[15]. To date, iTRAQ has been applied to a variety of sample
sets,including E.coli,mammaliancells,yeast,plantcells,and
human biological ﬂuids [16–22].
Therefore, in this study, we used iTRAQ to identify and
quantify diﬀerentially excreted urinary proteins in microal-
buminuricversusnormoalbuminurictype2diabeticpatients
and investigate the associations that would reﬂect the prog-
ress of DN. Afterward, those diﬀerentially excreted urinary
proteins have been conﬁrmed by 2-DE, followed by MALDI-
TOF/TOF, or validated by Western blot and MRM.
2.MaterialsandMethods
2.1. Urine Sample Preparation. Type 2 diabetic subjects (age
≥ 40 years) with or without microalbuminuria who were
patients at the Diabetes Center of Seoul National University
Hospital, Seoul, Republic of Korea, were enrolled in 2006.
Microalbuminuria patients were randomly selected out of
these outpatients, whereas normoalbuminuric patients were
selected to be matched to age, sex, body mass index (BMI),
and DM duration with microalbuminuric patients.
Forty-threesubjectswithdiabeticretinopathyandpersis-
tent microalbuminuria formed the microalbuminuria group
(MA). Persistent microalbuminuria was deﬁned as an albu-
min:creatinine ratio (ACR) between 30 and 300mg/g in
2 urine samples that were taken over 3 months. The nor-
moalbuminuria group (NA) comprised subjects who had no
diabetic retinopathy, did not use angiotensin inhibitors or
angiotensin receptor blockers that lowered albuminuria, and
showed no microalbuminuria in their urine in the past year
(urinary albumin < 30mg/g creatinine). Forty-three subjects
formed the NA group.
There were no signiﬁcant diﬀerences in age, sex, body
massindex,ordiabetesmellitusdurationbetweenthe2study
groups. Subjects with hematuria, uncontrolled hypertension
(blood pressure ≥ 140/90mmHg), uncontrolled hypergly-
cemia (glycated hemoglobin A1c ≥ 8.5%), urinary tract in-
fection, acute febrile illness, congestive heart failure, or
malignancy were excluded. Individuals who were receiving
peroxisome proliferator-activated receptor gamma agonists
were also excluded. Midstream urine of spot urine samples
were collected in sterile 50-mL tubes that contained 50μL
0.1mM PMSF (serine protease inhibitor) and 500μL1m M
sodium azide from 86 patients and were stored at −80◦C
until use. Informed consent was obtained from all subjects
after obtaining approval for the study from the Institutional
Review Board at Seoul National University Hospital.
Urine albumin and creatinine were measured in spot
urine samples by immunoturbidimetric method using the
TIA Micro Alb Kit (Nittobo, Tokyo, Japan) and enzymatic
creatinine assay (Roche, Mannheim, Germany), respectively,
on a Hitachi 7170 autoanalyzer (Hitachi, Tokyo, Japan).
For the iTRAQ and 2-DE experiments, pooled urine
samples,basedonaveragealbumin-to-creatinineratios,were
used; the clinical characteristics of the study subjects are
summarized in Table 1. Because the protein concentration
of each urine sample varied widely, depending on the urine
volume in the morning, equal amounts of total protein from
eachpatientwerepooledtopreparetheurinesamples(NA1–
NA4 and MA1–MA4).
To prepare the protein samples, approximately 50 mL
aliquots of normoalbuminuric and microalbuminuric urine
were centrifuged at 3000g for 30min at 4◦C. Supernatants
were ﬁltered through a 0.22μmM I L L E XG Pm e m b r a n e
(Millipore,Carrigtwohill,Cork,Ireland)andconcentratedto
3mL in an Amicon ultraﬁltration cell (YM2, 3kDa MW cut-
oﬀ, Millipore). The concentrated urine samples were then
desalted by dialysis twice using a Slide-A-Lyzer dialysis cas-
sette kit (3.5kDa, Pierce, Rockford, ILUSA) against 1000 vol-
umes of distilled water, containing 0.1mM PMSF (serine
protease inhibitor) and 1mM β-ME, at 4◦C. Proteins in the
dialyzed urine were precipitated with 5 volumes of acetone
for 4hrs at −20◦C, and the resulting pellets were washed 3
times with cold acetone; the supernatants were discarded.
2.2. Labeling with iTRAQ Reagents. Aliquots of 100μgo f
protein were reduced, alkylated, digested, and labeled accor-
ding to the manufacturer’s instructions (Applied Biosystems,
Foster City, CA, USA). Brieﬂy, 1μL of denaturant (2% SDS)
and 1μL of reducing reagent (50mM tris-[2-carboxyethyl]
phosphine) were added to each sample and incubated for
1hrat60 ◦C. Each sample was allowed to cool at room tem-
perature, and 1μL of cysteine blocking reagent (200mM
methyl methanethiosulfonate (MMTS) in isopropanol) wasExperimental Diabetes Research 3
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added and incubated for 20min at room temperature. The
tubes were digested with trypsin (Promega, Madison, WI,
USA) at a protein-to-enzyme ratio of 10:1 at 37◦Co v e r -
night, and the contents of one vial of iTRAQ reagent, dis-
solved in 70μL of ethanol, were added to each peptide mix-
ture and incubated for 1hr at room temperature.
In this study, 3 iTRAQ experiments were performed. The
detailed iTRAQ labeling strategy is summarized for the spec-
iﬁed NA/MA urine samples in Figure 1 and Table 1;i T R A Q
Experiments 1, 2, and 3 were performed for labeling (a)
and (b), (c) and (d), and (e), respectively. Each normoalbu-
minuric peptide was labeled with iTRAQ reagents 114, 115,
and 116, and the microalbuminuric peptide was labeled with
iTRAQ reagents 115 and 117 (Figure 1). The 2 sample sets
(microalbuminuric and normoalbuminuric) were combined
and dried. To analyze the proteome quantitatively using
iTRAQ labeling, we determined the labeling eﬃciency, as
described [23]; the number of possible labeling sites (the
N-termini of all peptides and lysine side chains) in 21,610
peptides were compared manually with that of completely
labeled sites, represented by the Pro GroupTM Algorithm in
ProteinPilot.
2.3. Strong Cation Exchange Chromatographic Fractionation.
iTRAQ-labeled samples were subjected to LC-MS/MS at the
National Instrumentation Center for Environmental Man-
agement, Seoul National University, and fractionated using
strong cation exchange (SCX) chromatography, as follows.
Dried samples were reconstituted in 500μLo fb u ﬀer A
(25%v/vacetonitrile(ACN)and5mMammoniumformate,
adjusted to pH 2.7 with formic acid) and loaded onto a
PolySULFOETHYL A column (4.6mm id × 100mm, 5μm,
200 ˚ A; PolyLC, Columbia, MD, USA) in a HP1100 series
HPLC (Agilent Technologies, Palo Alto, CA, USA). The col-
umn was equilibrated for 5min in buﬀer A, and the peptides
were eluted using a gradient of 0% to 30% buﬀer B (25% v/v
ACN and 1M ammonium formate [pH 3] with formic acid)
over 80min and 30% to 90% buﬀer B for 40min at a ﬂow
rate of 0.7mL/min. Absorbance was monitored at 280nm,
and the fractions were collected every 2min after injection.
2.4. LC-MS/MS Analysis. Fractions were reconstituted in
solvent A and injected into an LC-ESI-MS/MS system. LC-
MS/MS was performed using an integrated system, which
consisted of an autosampler switching pump and a microp-
ump (Tempo Nano LC system; Applied Biosystems) with
a hybrid quadrupole-TOF LC-MS/MS spectrometer (QStar
Elite; Applied Biosystems) that was equipped with a nano-
electrospray ionization source (Applied Biosystems) and ﬁt-
ted with a 10μm fused silica emitter tip (New Objective,
Woburn, MA, USA).
Peptides were ﬁrst trapped on a Zorbax 300SB-C18 trap
column (300μmi d× 5mm, 5μm, 100 ˚ A; Agilent Technolo-
gies), washed for 10min with 98% solvent A (water/ACN
[98:2 v/v] and 0.1% formic acid) and 2% solvent B (water/
ACN [2:98 v/v] and 0.1% formic acid) at a ﬂow rate of
10μL/min, and separated on a Zorbax 300SB-C18 capillary
column (75μmi d× 150mm, 3.5μm, 100 ˚ A) at a ﬂow rate of
300nL/min. The LC gradient was run at 2% to 35% solvent
B over 120min and from 35% to 90% over 10min, followed
by 90% solvent B for 15min, and ﬁnally 5% solvent B for
35min. The resulting peptides were electrosprayed through
a coated silica tip (New Objective) at an ion spray voltage of
2300eV.
Fordataacquisition,themassspectrometerwassetinthe
positive ion mode at a selected mass range of 400–1600m/z
for a 1sec TOF-MS survey scan to detect precursor ions. The
5 most abundant peptides (count >20) with charge states of
+2 to +4 were selected to perform the information-depen-
dent acquisition (IDA) of MS/MS data. Once selected, the
precursorionsweredynamicallyexcludedfor60secatamass
tolerance of 100ppm.
2.5. Data Analysis. Data ﬁle processing, protein identiﬁca-
tion, and relative abundance quantiﬁcation were performed
using ProteinPilot v.2.0.1 (Applied Biosystems; MDS-Sciex,
Concord,Canada)andtheParagonalgorithm[24].Database
searches were performed against the Celera human database
(human KBMS 5.0, 2005-03-02; a total of 187,748 entries
provided by Applied Biosystems). The search parameters
used were: a peptide and fragment ion mass tolerance of
0.2Da; 1 missed trypsin cleavage; ﬁxed cysteine modiﬁcation
by MMTS; variable oxidation of methionine; and iTRAQ
labeling of the N-termini of peptides and lysine side chain
residues.
The conﬁdence threshold for protein identiﬁcation was
an unused ProtScore >1.3 (95% conﬁdence interval). Pro-
teinPilot computes a percentage conﬁdence that reﬂects the
probability that a hit is a false positive; thus, at the 95% con-
ﬁdence level, the false positive identiﬁcation rate is approx-
imately 5% [24, 25]. Although this program automatically
accepts all peptides that have a conﬁdence level >1%, only
proteins with at least 1 peptide that had a conﬁdence level
>95% were initially recorded. At these low conﬁdence levels,
peptides do not identify a single protein by themselves but,
rather,supportproteinidentiﬁcationinthepresenceofother
peptides [24, 25]. Quantiﬁcation results were reported only
whentheerrorfactor(EF)was<2,whichindicatesastandard
deviation of quantiﬁcation <20%.
2.6. GO Ontology Analysis. The “biological process” and
“molecular function” classiﬁcations were analyzed using
PANTHER ID numbers (http://www.pantherdb.org/), pro-
vided in the ProteinPilot output when a Celera human data-
baseisused.Toconstructagraphicalrepresentationofdiﬀer-
entially excreted proteins, MultiExperiment Viewer (Version
4.3) was used, allowing us to generate a “heatmap” of diﬀer-
entially excreted proteomes (http://www.tm4.org/mev/).
2.7. 2-DE Urinary Proteome and PMF Analysis. Urine sam-
ples were pooled from 16 type 2 diabetic patients with nor-
moalbuminuriaand16type2diabeticpatientswithmicroal-
buminuria. The characteristics of the pooled urine samples
for 2-DE are shown in Figure 1 and Table 1. For the PMF
analysis, a MALDI-TOF/TOF mass spectrometer (ABI 4700
Proteomics Analyzer, Applied Biosystems) was used as des-
cribed in our previous papers [26, 27].Experimental Diabetes Research 5
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Figure 1: Workﬂow of iTRAQ, 2-DE, Western blot, and MRM of the urinary proteome. For analysis of the urinary proteome, 3 iTRAQ
experimentswereperformed,2-DE,Westernblot,andMRMwereconductedtoconﬁrmandvalidatetheiTRAQresults.iTRAQexperiments
1, 2, and 3 were performed, labeled (a) and (b), (c) and (d), and (e), respectively, wherein 3 biological replicates (labeled (a), (d), and (e),
resp.), technical replicate 1 (labeled (a) and (c)), and technical replicate 2 (labeled (b) and (d)) were performed in microalbuminuric versus
normoalbuminuric urine. 2-DE, Western blot, and MRM analysis of the urinary proteome were conducted using labeled (f), (g), and (h),
respectively.
2.8. Western Blot Analysis. Twenty-four urine samples that
were matched for gender and age (NA: 6 females and 6
males, and MA: 6 females; 6 males) were selected from the
urine sample groups (NA1–NA4 and MA1–MA4, resp.) and
subjected to Western blot validation of the 6 representative
candidates from the iTRAQ experiments (Figures 1 and 6,
and Table 1). The primary antibodies were directed against
transferrin (1:500, AbFrontier, Seoul, Korea), ceruloplas-
min (1:1000, AbFrontier), α1-antitrypsin (1:1000, AbFron-
tier), vitamin D-binding protein (1:1000, AbFrontier), α1-
acid glycoprotein (1:2000, AbFrontier), and haptoglobin
(1:1000, AbFrontier).
2.9. Candidate Validation Using Multiple Reaction Monitor-
ing. In addition to Western blot, multiple reaction moni-
toring (MRM) was performed to verify the candidate bio-
markers using 9 NA and 14 MA urine samples from the
urine sample groups (NA1–NA4 and MA1–MA4, resp.)
(Figure 1 and Table 1). In our MRM experiment [28], triple
quadrupole linear ion trap MS (4000 Qtrap, coupled with
a nano Tempo MDLC, Applied Biosystems) was performed;
the detailed procedure is previously described [28]. Data
were processed using the MultiQuant program (Applied
Biosystems, version 1.0), and each peak area of the transi-
tions was normalized to an input internal standard (Q1/Q3
transitionsat542.3/636.3m/z forbeta-galactosidasepeptide)
[28].Inthestatisticalanalysis,receiveroperatingcharacteris-
tic (ROC) curves and interactive plots were generated using
Medicalc (MedCalc Software, Mariakerke, Belgium, version
10.0.1.0).
3. Results
3.1. Identiﬁcation of Urinary Proteomes from Normoalbumin-
uric and Microalbuminuric Patients. For the iTRAQ exper-
iments, 3 biological replicates (biological replicate 1 was6 Experimental Diabetes Research
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Figure 2: Correlation between the 2 technical replicates and determination of the cutoﬀ value for signiﬁcant fold changes. (a) Plots of
iTRAQ ratios for two technical replicates. Forty-four proteins were commonly observed from technical replicate 1 (labeled 115/114), and 26
proteins were commonly observed from technical replicate 2 (labeled 117/116). These diﬀerentially excreted proteins (P value < 0.05, more
than two unique peptides: >95%) were plotted in the linear dynamic range. The technical variations yielded a correlation coeﬃcient of r2
= 0.9527 and r2 = 0.9178 between iTRAQ experiments 1 and 2, respectively. (b) The % variations for the common proteins from the two
technicalreplicates.The44and26commonproteinsfromthe2technicalreplicateswereusedasinputstocalculate%variations.Thevertical
axis represents the number of proteins, and the horizontal axis denotes % variation. Ninety percent of the proteins fell within 25% of the
respective experimental variation. Thus, we considered a fold-change of >1.25 or <0.80, a meaningful cutoﬀ that represented actual diﬀeren-
ces in the iTRAQ experiments.
labeled (a), replicate 2 was labeled (d), and replicate 3 was
labeled (e)); 2 technical replicates (technical replicate 1 was
labeled (a) and (c), replicate 2 was labeled (b) and (d)) were
generated from normoalbuminuric and microalbuminuric
urine(Figure 1).The3biologicalreplicateswereusedtopro-
ﬁle and quantitate the urinary proteome; the 2 technical rep-
licates were used solely to determine the cutoﬀ for signiﬁcant
fold-changes.
Seven hundred ten proteins were identiﬁed from 21,610
peptides of the 3 combined biological replicates at a mini-
mum conﬁdence level of 95% (unused ProtScore > 1.3). Of
the proteins that were identiﬁed by iTRAQ, 27% comprised
1-peptide proteins; 14% was 2-peptide proteins; 8% was 3-
peptide proteins; 5% was4-peptide proteins; 46% comprised
proteins that had 5 or more peptides. In our iTRAQ experi-
ment, 83 proteins (unused ProtScore > 1.3) were common to
all 3 biological replicates at a minimum conﬁdence level of
95%, using 3 diﬀerent pooled urine samples.
3.2. Determination of Cutoﬀ for Signiﬁcant Fold-Change in
iTRAQ Experiments. To generate the quantitative proteome
using iTRAQ labeling, we ﬁrst determined the labeling eﬃ-
ciency, which exceeded 98% (data not shown). Next, the cut-
oﬀ for signiﬁcant fold-change was determined based on the
2 technical replicates ((a) and (c) of iTRAQ experiment 1,
(b); (d) of iTRAQ experiment 2) (Figure 1). In the 2 replicate
experiments, the number of commonly identiﬁed proteins
was 173 (2 [115/114] ratios from technical replicate 1) and
107 (2 [117/116] ratios from technical replicate 2), and the
number of selected proteins was 44 (2 [115/114] ratios from
technical replicate 1) and 26 (2 [117/116] ratios from tech-
nical replicate 2), which were chosen based on the following
criteria: it contained more than 2 unique peptides (>95%),
and P value <0.05 for the 115/114 and 117/116 reporter ions.
The 70 proteins were used to monitor technical variations
and conﬁrm the threshold for meaningful diﬀerences.
The technical variations for the 115/114 and 117/116
reporter ions, calculated using the ratios of the 44 and 26
commonly observed proteins between the 2 technical repli-
cates, were r2 = 0.9527 and r2 = 0.9178, respectively
(Figure 2(a)). Accordingly, 90% of the commonly observed
in the technical replicates fell within 25% of the respec-
tive experimental variation (Figure 2(b)). Therefore, we set
fold-change thresholds of >1.25 or <0.80 to identify true
diﬀerences between the expression of 115/114 and 116/117
reporter ions, as described in [23].
3.3. Diﬀerential Proteomes between Microalbuminuria and
Normoalbuminuria. In our iTRAQ study, we obtained div-
erse biomarker candidates from 3 pooled biological NA/MAExperimental Diabetes Research 7
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Figure 3: Comprehensive functional annotation of the diﬀerentially excreted proteome. The 196 quantitated urinary proteins were annota-
ted for the “biological process” (x-axis) and “molecular function” subcategories (y-axis) in a heatmap. The “biological process” and “mole-
cular function” categories comprised 8 and 13 subcategories, respectively. The 196 quantitated urinary proteins are individually assigned
into the “biological process” and “molecular function” subcategories.
urine samples (each pooled NA or MA urine sample con-
sistedof9individualurinespecimens;thus,the3pooledNA,
and 3 pooled MA urine samples comprised 54 diﬀerent indi-
vidual urine samples). Further, biomarker candidates were
conﬁrmed and validated by 2-DE, Western blot, and MRM.
To analyze urinary proteomes in normoalbuminuria and
microalbuminuria subjects, 3 biological replicates were gen-
erated, wherein 196 proteins met the following criteria: P
value<0.05,EF<2,morethan2uniquepeptideswith>95%
conﬁdence level, and protein expression >1.25 or <0.80 for
all reporter ions; 99 and 97 proteins were upregulated and
downregulated, respectively (Appendix A).
These proteins were further analyzed by diﬀerential pro-
teomicexpression.Allquantiﬁedproteinswereclassiﬁedinto
“biological process” and “molecular function” subcategories
using the PANTHER classiﬁcation program, allowing us to
analyze phenotypic features and molecular functions bet-
ween microalbuminuria and normoalbuminuria (Figure 3).
Moreover, to visualize the comprehensive functional anno-
tations graphically, such as in a heatmap, the 196 proteins8 Experimental Diabetes Research
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Figure 4: Functional distribution of diﬀerentially excreted proteins in microalbuminuria versus normoalbuminuria. Functional classiﬁca-
tion of diﬀerentially excreted proteins into (a) “biological process” and (b) “molecular function.” Only 5 major subcategories for “biological
process” and “molecular function” are shown; each subcategory is presented as the percentage of up- and down-regulated proteins.
were ﬁrst categorized by “biological process,” and a second
dimensionwasaddedtocoordinatethe“molecularfunction”
subcategories (Figure 3). The 196 proteins constituted a pre-
liminary list of biomarkers; Figure 3 shows the expression
ratios of the iTRAQ dataset and diﬀerentially excreted pro-
teins in microalbuminuria versus normoalbuminuria urine.
3.4. Classiﬁcation of Urinary Proteomes in Microalbuminuria
versus Normoalbuminuria. The 196 proteins from the 3 bio-
logical replicates were categorized by PANTHER ID number
into “biological process” and “molecular function” groups;
certain subcategories are summarized in Figures 4(a) and
4(b).
The “biological process” subcategories accounted for 196
diﬀerentially excreted proteins, wherein “immunity and
defense” and “protein metabolism” represented 49 and 34
of the quantitated proteins, respectively—the 2 largest com-
ponents (Figure 3). Moreover, in the “biological process”
subcategories, “carbohydrate metabolism” (54.5%) and “sig-
nal transduction” (50%) were downregulated in microal-
buminuric versus normoalbuminuric urine (Figure 4(a)).
In contrast, 69.2%, 55.6%, and 55.1% of the 196 proteins
were upregulated in the “transport,” “protein metabolism,”
and “immunity and defense” subcategories, respectively
(Figure 4(a)).
The “molecular function” subcategories accounted for
196 diﬀerentially excreted proteins, in which “immunity”
and “receptor” represented 25 and 19 of the quantitated pro-
teins, respectively—the 2 largest components (Figure 3). In
the “molecular function” subcategories, “receptor” (68.4%)
and “signaling molecule” (57.1%) proteins were down-regu-
lated in microalbuminuric versus normoalbuminuric urine
(Figure 4(b)). In contrast, 72.0%, 58.8%, and 66.7% of the
196 proteins were up-regulated in the “immunity protein,”
“protease,” and “transfer/carrier protein” subcategories, res-
pectively (Figure 4(b)).
3.5. Diﬀerentially Excreted Urinary Proteins Are Associated
with Pathogenic Status. One hundred ninety-six tentative
biomarker candidates were diﬀerentially expressed, based on
the iTRAQ data, and they were characterized biologically
according to “biological process” and “molecular func-
tion.” Moreover, in a detailed association study of diabetic
nephropathy and diﬀerentially excreted proteins using ref-
erences and databases, we prioritized 10 candidates, of the
196diﬀerentiallyexcretedproteins(Figure 3),thatwereasso-
ciatedwithpathogenicstatus,suchasglomerularandtubular
dysfunction and other types of diseases. Accordingly, these
proteins were classiﬁed into categories of pathogenesis in
Table 2.
In the 3 biological replicates, transferrin (TF), cerulo-
plasmin precursor (CP), mannose-binding lectin-associated
serine protease-2 precursor (MASP2), alpha-1-antitrypsin
(A1AT), haptoglobin (HP), and basement membrane-spe-
ciﬁc heparin sulfate proteoglycan core protein (HSPG)w e r e
associated with glomerular dysfunction; except for MASP2
and HSPG, all were upregulated in microalbuminuric versus
normoalbuminuric urinary proteomes (Table 2).
Moreover, several diﬀerentially excreted proteins that
were related to tubular dysfunction, such as vitamin D-bind-
ing protein (VDBP) and alpha-1-acid glycoprotein 1 precur-
sor (AGP1) were selected for further validation. VDBP and
AGP1 were upregulated in microalbuminuria versus nor-
moalbuminuria (Table 2).
In addition, FABP (fatty acid-binding protein) and PSCA
(prostate stem cell antigen) correlate with other types of
disease, and PSCA was selected for further validation. In
this iTRAQ experiment, FABP was downregulated, whereas
PSCA expression increased in the microalbuminuric versus
normoalbuminuric urinary proteome (Table 2).
3.6. Identiﬁcation of Diﬀerentially Excreted Proteins Using 2-D
Gel Electrophoresis. Diﬀerential protein expression between
microalbuminuric and normoalbuminuric urine was also
measured using the 2-D gel electrophoresis in pooled NA4
and MA4 urine (Figure 1 and Table 1). In triplicate 2-DE
analysis (Figures 5(a) and 5(b)), two proteins (regulator of
telomere elongation helicase 1: RTEL1 and serum albumin:Experimental Diabetes Research 9
Table 2: Selected 10 diﬀerentially excreted proteins related to pathogenic status in microalbumiuric versus normoalbuminuric urines.
Pathogenic status N Number of unique peptidesa Accession numberb Gene namec MA:NA expression
iTRAQd 2-DEe WBf
Glomerular dysfunction
11 5 s p t |P02787 TF 1.86 — 4.66 ±1.41
24 7 S p t |P00450 CP 2.09 — 11.16 ± 0.38
3 209 spt|P01009 A1AT 1.42 — 3.36 ±0.03
44 9 s p t |P00738 HP 2.35 — 7.28 ±5.52
51 0 t r m |Q9UMV3 MASP2 0.29 0.10 ±0.005 —
6 235 spt|P98160 HSPG 0.68 0.28 ±0.041 —
Tubular dysfunction 79 s p t |P02774 GC, VDBP 2.44 — 2.88 ±0.11
8 414 spt|P02763 ORM1, AGP1 2.04 — 1.82 ±0.08
Other types of diseases 99 s p t |Q01469 FABP 0.29 0.27 ±0.037 —
10 5 trm|O43653 PSCA 1.70 — —
aThe numbers of unique peptides and MS/MS spectrum observed by ProteinPilot software were determined only for those peptides with ≥95% conﬁdence.
bAccessionnumbersrepresententriesintheHumanCDSdatabase(humanKBMS5.0,2005-03-02;atotalof187,748entriesprovidedbyAppliedBiosystems).
cGene name from the Expasy database correspond to protein accession number bfrom the Human CDS database (human KBMS 5.0, 2005-03-02; a total of
187,748 entries provided by Applied Biosystems). d−fRatio of diﬀerentially excreted protein for iTRAQ, 2-DE and WB in microalbumiuric versus normoalbu-
minuric urines, respectively.
ALB) were upregulated, and 5 proteins (basement mem-
brane-speciﬁc heparan sulfate proteoglycan core protein:
HSPG, fatty acid-binding protein: FABP, mannose binding
lectin-associated serine protease-2: MASP2,A M B Pp r o t e i n :
AMBP, and Fibulin-5: FBLN5) were downregulated in mic-
roalbuminuric urine (Figures 5(a) and 5(b)).
Of the 7 proteins that were identiﬁed by 2-DE, 4 had the
same pattern of diﬀerential excretion as in the iTRAQ expe-
riment. Speciﬁcally, the spots that corresponded to serum
albumin were upregulated by 2-DE (Figure 3(b), spots 1:
50.8 ± 15.3, 2: 17.5 ± 4.0, and 3: 14.2 ± 2.5) and iTRAQ
(iTRAQ: 3.09). In contrast, HSPG (spot 4: 0.28 ± 0.041 and
iTRAQ: 0.68), FABP (spot 5: 0.27 ± 0.037 and iTRAQ: 0.29),
and MASP2 (spot 6: 0.10 ± 0.005 and iTRAQ: 0.29) were
signiﬁcantly downregulated in both techniques (Table 3).
AMBP (spot 7) was downregulated by 2-DE (0.20 ± 0.002)
but upregulated in the iTRAQ experiment (1.44). Two pro-
teins were identiﬁed by 2-DE alone—regulator of telomere
elongation helicase 1 (spot 8: 3.0 ±0.5) was upregulated and
ﬁbulin-5 precursor (spot 9: 0.12±0.007) was downregulated
(Table 3).
3.7.ValidationofDiﬀerentiallyExpressedProteinsfromiTRAQ
by Western Blot. To validate the diﬀerentially excreted pro-
teins from the iTRAQ results, 6 proteins (TF, CP, A1AT,
VDBP, AGP1,a n dHP) that were associated with pathogenic
status were subjected to Western blot. The Western blot
results were consistent with the iTRAQ ﬁndings (Figure 6
and Table 2): TF (4.66 ± 1.41 and P<0.0005), CP (11.16 ±
0.38 and P<0.01), A1AT (3.36±0.03 and P<0.005), VDBP
(2.88±0.11 and P<0.05), AGP1 (1.82±0.08 and P<0.05),
andHP(7.28±5.52andP<0.05)wereupregulatedinmicro-
albumiuric versus normoalbuminuric urine.
3.8. MRM Validation for 7 Selected Biomarker Candidates.
To verify the 7 biomarker candidates (TF, CP, A1AT, HP,
VDBP,AGP1,andPSCA),MRMwasperformedusing9indi-
vidualnormoalbuminuricand14microalbuminuricsamples
(Figure 1 and Table 1). The peak area for each Q1/Q3 tran-
sition (Table 4) for the candidates was ﬁrst normalized to the
peak area of beta-galactosidase that was spiked with 50fmol
as the internal standard and compared between microalbu-
minuric versus normoalbuminuric samples.
MRM validation was assessed by interactive plots and
ROC curves, represented by the peak area of each Q1/Q3
transition. Figure 7 shows the interactive plots and ROC
curves for TF, CP, A1AT, VDBP, AGP1, HP,a n dPSCA with
regard to sensitivity, speciﬁcity, and relative concentrations
versus beta-galactosidase. In the ROC curves, TF, A1AT,
AGP1, HP,a n dPSCA had excellent area under the curve
(AUC) values(0.762, 0.849, 0.873, 0.754, and 0.825, resp.), as
did CP and VDBP, to a lesser extent (0.683 and 0.675, resp.)
(Figure 7). Particularly, the merged ROC curve combining
3 biomarker candidates (alpha-1-antitrypsin, alpha-1-acid
glycoprotein 1, and prostate stem cell antigen) resulted in the
improved AUC value of 0.921, which is greater than those of
the individual proteins (0.849, 0.873, and 0.825 for alpha-1-
antitrypsin, alpha-1-acid glycoprotein 1, and prostate stem
cell antigen, resp.) (Figure 8).
In the interactive plots, TF, CP, A1AT, VDBP, AGP1,a n d
PSCA were upregulated in microalbuminuric versus nor-
moalbuminuric urine, whereas HP was down-regulated. TF,
CP, A1AT, VDBP, AGP1,a n dPSCA had the same excretion
patterns by iTRAQ and western blot; conversely, HP had the
opposite excretion pattern.
4. Discussion
4.1. Diﬀerentially Excreted Proteomes between Microalbumin-
uria and Normoalbuminuria. To identify and quantify pro-
teins that were associated with diabetic nephropathy in mic-
roalbuminuric and normoalbuminuric urine, we used rela-
tive quantitative proteomic techniques, such as iTRAQ, 2-
DE, Western blot, and MRM. In our iTRAQ experiment,
710 urinary proteins were identiﬁed at a >95% conﬁdence
level, of which 196 were diﬀerentially excreted by >1.2510 Experimental Diabetes Research
Table 3: Diﬀerentially expressed proteins by 2-DE in microalbuminuria versus normoalbuminuria.
Gene namea Accession
numberb
Up-
/down-
regulated
Mol. Mass,
Da (pI)c
Peptides
matched
Total ion
C.I.%d
Ma/Na
(2-DE)f
Ma/Na
(iTRAQ)g
ALB P02768 Up 71317.2
(5.92) 2 100.00 50.8 ±15.33 . 0 9
ALB P02768 Up 71317.2
(5.92) 2 99.84 17.5 ±4.03 . 0 9
ALB P02768 Up 71317.2
(5.92) 2 100.00 14.2 ±2.53 . 0 9
HSPG P98160 Down 468527.5
(6.06) 2 100.00 0.28 ±0.041 0.68
FABP Q01469 Down 15496.7
(6.6) 1 97.76 0.27 ±0.037 0.29
MASP2 Q9UMV3 Down 75684.6
(5.47) 2 100.00 0.10 ± 0.005 0.29
AMBP P02760 Down 38974
(5.95) 2 99.91 0.20 ±0.002 1.44
RTEL1 Q9NZ71 Up 152278.2
(8.68) 1 96.77 3.0 ±0.5—
FBLN5 Q9UBX5 Down 50146.7
(4.58) 1 99.36 0.12 ±0.007 —
a−bGene name from the Expasy database correspond to protein accession number. bAccession numbers represent entries in the Human CDS database. cMole-
cular mass (mol. mass) is presented by Da, while isoelectric point stands for pI. dTotal ion score and total ion CI % for MALDI-TOF/TOF were calculated
usingGPSv3.5intheMASCOTsearchprogram(v2.0). f−gRatioofdiﬀerentiallyexcretedproteinfor2-DEandiTRAQinmicroalbumiuricversusnormoalbu-
minuric urines, respectively. Data are expressed as the mean ± SD.
Table 4: Parameters of MRM Experiment for seven candidate proteins.
Protein name Q1a Q3b Sequencec Fragmentd Chargee CEf
Transferrin
482.8 682.4 APNHAVVTR y6 2+ 26
315.2 558.3 AVGNLR y5 2+ 19
315.2 459.3 AVGNLR y4 2+ 19
Ceruloplasmin 686.4 1080.0 GAYPLSIEPIGVR y10 2+ 35
686.39 870.5 GAYPLSIEPIGVR y8 2+ 35
Alpha-1-antitrypsin
555.81 997.5 LSITGTYDLK y9 2+ 29
555.81 797.4 LSITGTYDLK y7 2+ 29
393.2 587.3 VVNPTQK y5 2+ 22
393.2 473.3 VVNPTQK y5 2+ 22
Haptoglobin precursor 729.8 1084.5 NLFLNHSENATAK y10 2+ 37
352.2 517.3 VSVNER y4 2+ 20
Vitamin D-binding protein 400.2 700.4 VLEPTLK y6 2+ 26
400.2 587.3 VLEPTLK y5 2+ 26
Alpha-1-acid glycoprotein 1
556.8 811.4 SDVVYTDWK y6 2+ 29
580.8 974.5 WFYIASAFR y8 2+ 31
580.8 827.4 WFYIASAFR y7 2+ 31
Prostate stem cell antigen 501.0 830.5 AVGLLTVISK y8 2+ 30
501.0 660.4 AVGLLTVISK y6 2+ 30
a−bQ1 and Q3 (m/z) represent the Q1 and Q3 transitions for proteotypic peptide, respectively. cSequence represents the sequence of proteotypic peptide for
targetprotein. dFragmenttypeindicatestheiontypeoftheQ3transition. eChargerepresentsthechargestateofprecursorion. fCErepresentscollisionenergy.
or <0.80—99 and 97 proteins were up- and down-regulated,
respectively (Appendix A).
Recently, the Urinary Protein Biomarker (UPB) database
was constructed and published, in which 205 publications
were curated manually [29]. Using this database, we can
easily determine whether a biomarker candidate has been
identiﬁedbyanothergroupforthesamediseaseandevaluate
its disease speciﬁcity. Thirty-six of the 196 quantiﬁed pro-
teins from our iTRAQ experiment were registered in the
UPB database; the remaining 160 proteins were not listed.Experimental Diabetes Research 11
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Figure 5: Diﬀerentially excreted proteins by 2-DE in microalbuminuria versus normoalbuminuria. (a) Representative whole 2-DE images
of normoalbuminuric (NA) and microalbuminuric (MA) urine. Total protein (100μg) samples were loaded onto IPG strips (pH 4–7, nonli-
near) for IEF and separated in the second dimension on a 12% polyacrylamide gel. The horizontal and vertical axes represent pI and
molecular weight, respectively. The arrowed numbers denote for diﬀerentially excreted proteins and correspond to the proteins in Table 3.
(b)Magniﬁedsectionsofdiﬀerentiallyexcretedproteinsinthe2-DEgel.Somearrowedproteinsinthe2-DEgel(Figure 5(a))weremagniﬁed
side by side to compare their relative expression.
Subsequently, 196 diﬀerentially excreted proteins yielded 10
preliminary biomarker candidates for further validation.
The “molecular function” subcategories accounted for
196 diﬀerentially excreted proteins, of which “immunity”
represented 25 of the quantitated proteins—the largest com-
ponent (Figure 3). This proportion reﬂects the increased in-
ﬂammatory reactions and higher vascular lesion counts in
kidneys during the development of diabetic nephropathy.
Through detailed association searches between diabetic nep-
hropathy and the 196 diﬀerentially excreted proteins using
relevantdatabasesandreferences,weidentiﬁedandclassiﬁed
several biomarker candidates that were associated with path-
ogenic status, such as glomerular and tubular dysfunction
and other types of disease (Table 2).
Consequently, 10 proteins were selected for preliminary
validation studies such as 2-DE, Western blot, and MRM.12 Experimental Diabetes Research
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Figure 6: Validation using Western blot for six representative diﬀerentially excreted proteins. The concentrations of transferrin (a), cerulo-
plasmin (b), α1-antitrypsin (c), vitamin D-binding protein (d), α1-acid glycoprotein (e), and haptoglobin (f) are signiﬁcantly higher in
microalbuminuric patients versus normoalbuminuric urine. The relative intensities on the vertical axis indicate normalized values versus
the representative control. Each bar represents the mean ± SEM, based on the relative intensities of the gel bands. Statistical signiﬁcance for
the diﬀerences (∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.005; ∗∗∗∗P<0.0005) were determined by paired Student’s t-test. Two representative NA
and MA blots are shown at the top of the bar graphs.Experimental Diabetes Research 13
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Figure 7: ROC curves and interactive plots for MRM validation in normoalbuminuric versus microalbuminuric urine. Seven biomarker
candidates (TF, CP, A1AT, VDBP, AGP1, HP,a n dPSCA) were validated by MRM, in which 9 normoalbuminuric and 14 microalbuminuric
urine samples were used. (a)–(g) Interactive plots and ROC curves for TF, CP, A1AT, VDBP, AGP1, HP,a n dPSCA. In the ROC curves, the
solidlinesrepresentthecorrespondingscoreinsensitivity(x-axis)and100-speciﬁcity(y-axis).Intheinteractiveplots,the y-axisindicatesthe
normalized concentration of the target protein against the spiked internal standard (50 fmol of beta-galactosidase peptide). Sens. and Spec.
represent the sensitivity and speciﬁcity for the target proteins, respectively. The AUC values are shown inside the ROC curves.
For example, 3 proteins (HSPG, FABP,a n dMASP2) that
were identiﬁed by 2-DE had the same pattern of diﬀerential
excretion in the 2-DE and iTRAQ experiments (Table 2). Six
diﬀerentially excreted proteins (TF, CP, A1AT, VDBP, AGP1,
and HP) were validated by Western blot, for which the
patterns of excretion were consistent with the iTRAQ results
(Table 2).
Recently, an optimized quantitative proteomic strategy
in urinary proteomic analysis was proposed for urine bio-
markerdiscoveryusingasmallsetofsamples[21].According
to this report, the initial amount of proteins that is analyzed
and the precipitation method (methanol precipitation) of
the urine proteins are critical. Notably, our preparation met-
hods for urinary proteomes approximated this optimized14 Experimental Diabetes Research
Alpha-1-antitrypsin
AUC: 0.849
0
20
40
60
80
100
S
e
n
s
i
t
i
v
i
t
y
100-speciﬁcity
0 2 04 06 08 0 1 0 0
(a)
Alpha-1-acid glycoprotein 1
AUC: 0.873
0
20
40
60
80
100
S
e
n
s
i
t
i
v
i
t
y
100-speciﬁcity
0 2 04 06 08 0 1 0 0
(b)
Prostate stem cell antigen
AUC: 0.825
0
20
40
60
80
100
S
e
n
s
i
t
i
v
i
t
y
100-speciﬁcity
02 0 4 0 6 0 8 0 1 0 0
(c)
Multiplex assay
A1AT + PSCA + A1AG
A1AG
A1AT
PSCA
AUC: 0.921
0
20
40
60
80
100
S
e
n
s
i
t
i
v
i
t
y
100-speciﬁcity
0 2 04 06 08 0 1 0 0
(d)
Figure 8: ROC curves for three candidate biomarkers and the 3-marker panel. MRM validation was performed for (a) alpha-1-antitrypsin,
(b) alpha-1-acid glycoprotein 1, (c) prostate stem cell antigen, and (d) their combination, generating AUC values of 0.849, 0.873, and 0.825,
respectively, whereas the combination resulted in a merged AUC of 0.921.
protocol, although we used acetone precipitation instead of
methanol precipitation.
Nevertheless, an advantage of our study was that we used
a large collection of urine samples from 86 diabetic patients
to perform 3 iTRAQ experiments, including 3 biological rep-
licates and 2 technical replicates, resulting in more reliable
statistical signiﬁcance.
4.2.DiﬀerentiallyExcretedProteomeandGlomerularDysfunc-
tion. Glomerular dysfunction is caused by GBM thickening
and mesangial expansion due to ECM accumulation [2], and
several proteins, such as TF, CP, MASP2, A1AT, HP,a n d
HSPG, were associated with glomerular dysfunction.
Transferrin-to-creatinine and ceruloplasmin-to-creati-
nine ratios are known to reﬂect changes in renal hemody-
namics, and these ratios are signiﬁcantly higher microalbu-
minuric patient than normoalbuminuric patients [30]. This
result is caused by elevated intraglomerular hydraulic pres-
sure, which leads to the development of diabetic glomeru-
losclerosis [30–32]. Moreover, TF and CP were listed in the
UPB database, showing upregulation. TF is associated with
diabetic nephropathy, normoalbuminuric type 2 diabetes,
kidney calculi, and ureteropelvic junction obstruction,
whereas CP is linked to diabetic nephropathy and normoal-
buminuric type 2 diabetes. In our iTRAQ and 2-DE, TF and
CP urinaryproteinswerecommonlyupregulatedinthecom-
parison of microalbuminuric and normoalbuminuric uri-
nary proteome (Table 2).
MASP2isaserumproteasethatactivatesthecomplement
cascade, which regulates the maintenance of glomerular per-
meability and the pathogenesis of focal segmental glomeru-
losclerosis [33]. MASP2 was not listed in the UPB database,
and in this iTRAQ and 2-DE, this protein was commonly
downregulatedincomparisonofmicroalbuminuricandnor-
moalbuminuric urinary proteome (Table 2).
A1AT is a serine protease inhibitor, which prevents neu-
trophilelastasebydegradingECMproteins,whichmaintains
vascular elasticity and glomerular integrity [13, 34]. In a pre-
vious study, A1AT excretion was elevated in microalbumi-
nuria, which can cause matrix molecules to accumulate [35].
A1AT was also listed in the UPB database, showing upreg-
ulation; it is associated with diabetic nephropathy, severe
acute pancreatitis, kidney calculi, nephrotic syndrome, and
ureteropelvic junction obstruction. In our iTRAQ andExperimental Diabetes Research 15
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Western blot, A1AT was also upregulated in the comparison
of microalbuminuric and normoalbuminuric urinary pro-
teome (Table 2).
Haptoglobin (HP) is an acute phase protein that binds to
free hemoglobin (Hb) with the highest aﬃnity. Formation of
theHb-HPcomplexpreventsthelossofrenalironandoxida-
tivedamagethataredrivenbyfreeHb.Speciﬁcally,HP medi-
ates complement-dependent podocyte damage [36]. Thus,
complementactivationresultsinthereleaseofproteases,oxi-
dants, and growth factors, damaging the functional integrity
of the GBM. HP, which was downregulated and is associated
with diabetic nephropathy and type 2 diabetes mellitus,
appeared in the UPB database. However, in our iTRAQ and
Western blot, HP was commonly upregulated in the compa-
rison of microalbuminuric and normoalbuminuric urinary
proteome (Table 2).
HSPG is present in the basement membrane of every vas-
cularized organ, including the GBM. The highly negatively
charged side chains of HSPG are important determinants for
the charge-selective permeability of the GBM [37]. Under
hyperglycemic conditions, the loss of HSPG from the GBM
alters the charge-selective properties of the glomerular cap-
illary, causing increased ﬁltration of negatively charged
albumin [37, 38]. HSPG is not registered in the UPB data-
base, and in our iTRAQ and 2-DE, HSPG was commonly
downregulated in the comparison of microalbuminuric and
normoalbuminuric urinary proteome (Table 2).
4.3. Diﬀerentially Excreted Proteome and Tubular Dysfunction
andOtherTypesofDiseases. Low-molecular-weightproteins,
such as VDBP and AGP1, are associated with kidney tubular
dysfunction and were commonly upregulated in the iTRAQ
and Western blot (Table 2). Unlike high-molecular-weight
proteins, they are ﬁltered in the glomerulus on the basis of
charge selectivity and pore size of the GBM and are reab-
sorbed into proximal renal tubules under normal conditions16 Experimental Diabetes Research
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[38]. If reabsorption is impaired, however, these proteins can
be overexcreted into urine.
VDBP is a multifunctional serum glycoprotein and is an
important mediator in immunopathogenesis because it is
associated with immunoglobulin receptors on the surfaces
of B- and T-lymphocytes [12]. Moreover, VDBP binds to
circulatingvitaminDmetaboliteswithhighaﬃnity[39],and
VDBP-bound25-hydroxyvitaminD3crossestheGBMandis
reabsorbed byproximaltubularcellsin amegalin-dependent
manner, suggesting that it controls renal uptake and the acti-
vation of metabolites [4, 40]. VDBP, also listed in the UPB
database, was upregulated and is associated with diabetic
nephropathy and Dents disease. In our iTRAQ and Western
blot, VDBP was commonly upregulated in the comparison
of microalbuminuric and normoalbuminuric urinary pro-
teome (Table 2).
AGP1 is synthesized in response to systemic tissue injury,
inﬂammation, and infection, like most other acute phase
proteins [7, 41]. Further, increased levels of AGP1 reﬂect
elevated levels of cytokines, such as interleukin-1 (IL-1),
IL-6, and tumor necrosis factor alpha (TNF-α), which are
associatedwithtype2diabetes[7].Astudyhasdemonstrated
that AGP1 is an indicator of tubular disorder in multiple
myeloma [42], and another has shown that serum and uri-
nary AGP1 levels are elevated in type 2 diabetic patients with
kidney disorders [5, 7]. AGP1 was listed in the UPB data-
base, showing upregulation, and is associated with diabetic
nephropathy, diabetic kidney disorder, preeclampsia, and
acute appendicitis. In our iTRAQ and Western blot, AGP1
was also commonly upregulated in the comparison of mic-
roalbuminuric and normoalbuminuric urinary proteome
(Table 2).
FABP (fatty acid-binding protein: FABP) correlated with
other types of diseases [43] and was also chosen for further
validation. FABP was not listed in the UPB database, and in
this iTRAQ and 2-DE, FABP was commonly downregulated
inthecomparisonofmicroalbuminuricandnormoalbumin-
uric urinary proteome (Table 2).
PSCA is highly expressed in the prostate and, to a lesser
extent, in the bladder, placenta, colon, kidney, and stomach.
Moreover, it is upregulated in prostate cancer and is detected
in cancers of the bladder and pancreas [44]. PSCA was not
listed in the UPB database but was upregulated in the micro-
albuminuric versus normoalbuminuric urinary proteome in22 Experimental Diabetes Research
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Figure 17
our iTRAQ experiment (Table 2). No relationship between
prostate stem cell antigen and diabetic nephropathy has been
reported.
4.4. Validation of Diﬀerentially Excreted Proteins Using MRM.
FortheMRMexperiments,weusedabacterialbetagalactosi-
dase peptide as the internal standard for relative quatitation
[28]. Seven preliminary biomarker candidates (TF, CP,
A1AT, VDBP, AGP1, HP,a n dPSCA)w e r ec o n ﬁ r m e di n9
normoalbuminuric and 14 microalbuminuric urine samples
by MRM (Figure 7).
In the interactive plots, TF, CP, A1AT, VDBP, AGP1,
and PSCA were preferentially excreted in microalbuminuria
versus normoalbuminuria, whereas HP was downregulated.
TF,CP,A1AT,VDBP,andAGP1 hadthesamepatternofexc-
retion in the iTRAQ and western analysis, and HP had the
opposite pattern between the MRM and Western analysis.
HP consistsofα-chain(aminoacidsequence:19–160)andβ-
chain (aminoacid sequence: 162–406), which are connected
by disulﬁde bridges. In the MRM experiment, the transition
(amino acid sequence: 203–215) in the β-chains was used
for the relative quantitation of HP. In contrast, portions of
both the α-chain and β-chain were used in the iTRAQ quan-
titation (sequence coverage: 31.0%), and an antibody that
targeted a sequence in the α-chain was used for the Western
blot analysis. It is conceivable that these disparate targets
resulted in contradictory patterns between iTRAQ, Western
blot, and MRM. Regardless of the methods or targets, repro-
ducible patterns must be obtained with each method.
Furthermore,weperformedamultiplexassaytoimprove
AUC values with 3 biomarker candidates (alpha-1-antitry-
psin,alpha-1-acidglycoprotein1,andprostatestemcellanti-
gen), obtaining a merged AUC value of 0.921, which is
greater than those of the individual proteins (0.849, 0.873,
and 0.825 for alpha-1-antitrypsin, alpha-1-acid glycoprotein
1, and prostate stem cell antigen, resp.) (Figure 8).
Althoughourresultsrequirefurthervalidationinalarger
collection of urine samples that contains various control
samples, it appears that A1AT, AGP1,a n dPSCA are excellent
biomarker candidates, with AUC values> 0.8; combining the
candidates improved the AUC value of 0.921. Accordingly,
the other diﬀerentially expressed proteins from our iTRAQ
experiment in Appendix A are potential candidates for fur-
ther validation in obtaining DN biomarkers.24 Experimental Diabetes Research
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5. Conclusions
Microalbuminuria is used as a noninvasive index for the
detection of diabetic renal disease. Yet, more speciﬁc and
a c c u r a t eb i o m a r k e r sf o rD Na r er e q u i r e d ,p a r t i c u l a r l yi n
type 2 diabetic patients, due to several reasons, including
nonspeciﬁc detection in nondiabetic renal disease, cardio-
vascular disease, inﬂammation, and hypertension. In our
iTRAQ experiments, 710 urinary proteins were identiﬁed at
a >95% conﬁdence level, of which 196 were diﬀerentially
excretedby>1.25or<0.80—99and97proteinswereup-and
down-regulated, respectively (Appendix A).
We prioritized 196 proteins to select preliminary bio-
marker candidates by characterizing them with regard to
“biological process” and “molecular function” and associ-
ating them with pathogenesis. Consequently, 10 proteins
were selected. To conﬁrm and validate these candidates,
2-DE, Western blot, and MRM were performed. Based
on the MRM results, A1AT, AGP1,a n dPSCA, which had
AUC values > 0.8, are good biomarker candidates, and we
improved the AUC value to 0.921 on combining the 3 pro-
teins.
Further validation studies on other diﬀerentially excreted
proteins might contribute to a greater understanding of the
mechanism of renal dysfunction and its association with the
pathogenesis of DN, facilitating the development of better
biomarkers for DN.
Appendices
A. DifferentiallyExcreted Urinary
Proteome in Microalbumiuricversus
NormoalbuminuricUrine
For more details, see Table 5.
B. Mascot Search andROC Curvesfor
Each Transition of MRM
To verify the MRM validation, we analyzed minimum of 2
transitions for each biomarker candidate protein.
Results from Mascot search and ROC curves for each
transition are summarized in Figures 9, 10, 11, 12, 13, 14,
15, 16, 17, 18,a n d19.Experimental Diabetes Research 25
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Table 5: Diﬀerentially excreted urinary proteome in microalbumiuric versus normoalbuminuric urine.
N Unique peptidesa Accession numberb Protein name Ratioc MA:NA Pvald MA:NA EFe MA:NA
1 651 spt|P02768 Serum albumin 3.09 0.00 1.04
2 337 gb|AAF01333.1 Serum albumin 0.36 0.00 1.08
3 669 trm|Q8N4N0 Alpha-2-glycoprotein 1 1.48 0.00 1.02
4 639 rf|NP 003352.1 uromodulin 0.72 0.00 1.04
5 269 emb|CAA42438.1 Zn-alpha2-glycoprotein 1.80 0.00 1.06
6 235 spt|P98160 HSPG 0.68 0.00 1.04
7 209 spt|P01009 Alpha-1-antitrypsin 1.42 0.00 1.04
8 414 spt|P02763 Alpha-1-acid glycoprotein 1 2.04 0.00 1.03
9 265 spt|P02788 Serotransferrin 2.46 0.00 1.10
10 46 spt|P02760 AMBP protein 1.44 0.00 1.12
11 300 spt|P07911 Uromodulin 0.24 0.00 1.08
12 106 prf|765044A Ig G1 H Nie 0.61 0.00 1.15
13 223 dbj|BAC85395.1 Unnamed protein product 1.37 0.00 1.10
14 217 emb|CAA29229.1 Alpha-1-acid glycoprotein 1 2.29 0.00 1.11
15 107 trm|Q5VU27 Heparan sulfate proteoglycan 2 2.00 0.00 1.18
16 306 spt|P07998 Ribonuclease pancreatic 0.80 0.00 1.08
17 62 spt|P41222 Prostaglandin-H2 D-isomerase 1.40 0.00 1.13
18 47 spt|P00450 Ceruloplasmin 2.09 0.00 1.12
19 117 prf|763134A Ig A1 Bur 1.60 0.02 1.39
20 46 cra|hCP1909255 Serine proteinase inhibitor 1.52 0.00 1.07
21 90 spt|P10451 Osteopontin 0.57 0.00 1.43
22 9 spt|P04746 Pancreatic alpha-amylase 0.41 0.00 1.33
23 39 spt|P02749 Beta-2-glycoprotein I 1.37 0.00 1.07
24 50 trm|Q9UII8 E-cadherin 1.36 0.00 1.12
25 34 rf|NP 006112.2 Keratin 1 0.60 0.00 1.16
26 88 spt|Q14624 ITIH4 0.78 0.00 1.08
27 21 trm|Q6N025 FN 1.27 0.01 1.20
28 21 trm|Q8N175 Keratin 10 0.67 0.00 1.27
29 34 emb|CAA48671.1 Alpha1-antichymotrypsin 1.64 0.00 1.17
30 50 spt|P00738 Haptoglobin 2.36 0.01 1.24
31 22 gb|AAA52014.1 Cholesterol esterase 0.46 0.00 1.10
32 63 spt|P05451 Lithostathine 1 alpha 1.54 0.00 1.05
33 31 trm|Q6PAU9 Kininogen 1 0.75 0.00 1.18
34 20 spt|P04217 Alpha-1B-glycoprotein 1.86 0.00 1.31
35 34 spt|P05155 Plasma protease C1 inhibitor 0.75 0.00 1.12
36 14 trm|Q8N473 Alpha 1 type I collagen 0.72 0.00 1.14
37 139 trm|Q6IB74 ORM2 protein 1.48 0.00 1.23
38 22 spt|Q8WZ75 Roundabout homolog 4 0.34 0.00 1.23
39 29 spt|P02791 Hemopexin 1.73 0.01 1.33
40 33 trm|Q6LBL5 GM2 activator protein 1.45 0.00 1.06
41 19 pdb|1HP7 A A Chain A, uncleaved alpha-1-antitrypsin 1.76 0.00 1.18
42 23 spt|P55290 Cadherin-13 0.76 0.00 1.13
43 21 trm|Q8IZY7 Poly-Ig receptor 0.63 0.00 1.36
44 25 spt|P05154 Plasma serine protease inhibitor 0.76 0.00 1.12
45 10 trm|Q96CZ9 Cadherin 11, type 2, isoform 1 preproprotein 0.44 0.00 1.50
46 16 gb|AAR84237.2 Truncated epidermal growth factor 0.48 0.00 1.25
47 35 spt|P24855 Deoxyribonuclease I 0.50 0.00 1.12
48 17 trm|Q7Z645 Collagen, type VI, alpha 1 0.51 0.00 1.17
49 15 dbj|BAA19556.1 Immunoglobulin light chain V-J region 1.69 0.01 1.38
50 33 emb|CAA23842.1 Unnamed protein product 1.43 0.00 1.05Experimental Diabetes Research 27
Table 5: Continued.
N Unique peptidesa Accession numberb Protein name Ratioc MA:NA Pvald MA:NA EFe MA:NA
51 32 spt|P08571 CD14 2.36 0.00 1.62
52 26 trm|Q6GMX2 Hypothetical protein 0.59 0.01 1.24
53 111 emb|CAA29873.2 Alpha-1-acid glycoprotein 2 2.25 0.00 1.18
54 7 trm|Q8WY99 Cathepsin C 1.58 0.00 1.17
55 11 spt|Q92820 Gamma-glutamyl hydrolase 0.54 0.01 1.33
56 13 spt|P15586 N-acetylglucosamine-6-sulfatase 1.30 0.02 1.23
57 10 gb|AAQ88523.1 AQGV3103 0.79 0.05 1.26
58 8 trm|Q8N2F4 Hypothetical protein PSEC0200 0.71 0.01 1.29
59 20 trm|Q6MZU6 Hypothetical protein DKFZp686C15213 0.39 0.00 1.28
60 27 trm|Q6LDS3 APS protein 1.34 0.00 1.08
61 9 pdb|1L9X D Structure Of Gamma-Glutamyl Hydrolase 0.69 0.00 1.12
62 15 spt|P07339 Cathepsin D 1.38 0.01 1.26
63 10 spt|P51884 Lumican 0.78 0.01 1.20
64 130 dbj|BAC85483.1 Unnamed protein product 0.73 0.00 1.14
65 9 pdb|1ATH B B Chain B, Antithrombin Iii 1.29 0.00 1.17
66 15 rf|NP 001822.2 Clusterin isoform 1 0.63 0.00 1.25
67 23 trm|Q5VW91 Decay accelerating factor for complement 1.26 0.00 1.09
68 7 spt|P54802 Alpha-N-acetylglucosaminidase 0.50 0.00 1.25
69 12 spt|Q16270 IGFBP-7 0.79 0.00 1.14
70 8 trm|Q5VZE3 Golgi phosphoprotein 2 0.38 0.02 1.46
71 10 spt|P05543 Thyroxine-binding globulin 1.27 0.00 1.11
72 9 spt|P02774 Vitamin D-binding protein 2.44 0.00 1.15
73 63 rf|NP 000573.1 Secreted phosphoprotein 1 0.58 0.00 1.24
74 56 spt|P02671 Fibrinogen alpha/alpha-E chain 0.67 0.00 1.11
75 10 trm|Q9UBG3 Tumor-related protein 0.32 0.00 1.67
76 15 trm|O00391 Quiescin Q6 0.77 0.03 1.25
77 36 trm|Q5VY30 Retinol binding protein 4, plasma 1.38 0.00 1.04
78 8 rf|NP 004675.2 SPARC-like 1 0.55 0.03 1.70
79 9 spt|Q92692 Herpesvirus entry mediator B 0.50 0.00 1.31
80 39 trm|Q96FE7 HGFL protein 0.73 0.00 1.15
81 6 spt|P43652 Afamin 4.67 0.00 1.33
82 24 pdb|1QDD A Lithostathine 1.73 0.00 1.20
83 24 spt|P10153 Nonsecretory ribonuclease 0.83 0.01 1.13
84 8 spt|P16278 Beta-galactosidase 1.50 0.00 1.20
85 7 trm|Q5VYK1 Collagen, type XII, alpha 1 0.75 0.00 1.15
86 9 emb|CAA37914.1 Precursor (AA-19 to 692) 1.91 0.01 1.62
87 15 trm|Q7Z5L0 Unnamed secretory protein 0.56 0.00 1.31
88 11 spt|P08236 Beta-glucuronidase 1.33 0.00 1.12
89 13 cra|hCP51001.2 superoxide dismutase 3 0.45 0.00 1.38
90 17 pir|S13195 Ganglioside M2 activator protein 1.33 0.00 1.18
91 12 cra|hCP1858145 Protein C receptor, endothelial 1.42 0.00 1.22
92 12 trm|Q6IAT8 B2M protein 1.48 0.00 1.08
93 7 trm|Q9Y5X6 Glutamate carboxypeptidase 1.47 0.00 1.04
94 13 spt|P06702 Calgranulin B 0.41 0.00 1.36
95 11 emb|CAB90482.1 Human type XVIII collagen 0.56 0.01 1.48
96 7 trm|O00533 Neural cell adhesion molecule 0.73 0.02 1.29
97 72 spt|P04745 Salivary alpha-amylase 1.25 0.00 1.12
98 40 spt|O75594 Peptidoglycan recognition protein 0.56 0.00 1.08
99 127 emb|CAA40946.1 Immunoglobulin lambda light chain 1.71 0.01 1.47
100 15 trm|Q9UJ36 Transmembrane glycoprotein 0.74 0.01 1.25
101 4 gb|AAH17802.1 SPRR3 protein 0.14 0.00 1.25
102 9 spt|Q01469 Fatty acid-binding protein 0.29 0.00 1.3428 Experimental Diabetes Research
Table 5: Continued.
N Unique peptidesa Accession numberb Protein name Ratioc MA:NA Pvald MA:NA EFe MA:NA
103 4 trm|Q6FGL5 LCN2 protein 1.36 0.01 1.33
104 10 trm|Q9UMV3 MBL-associated serine protease 2 0.29 0.00 1.34
105 10 gb|AAH30653.1 Cadherin 13, preproprotein 2.91 0.00 1.76
106 6 spt|Q9H8L6 Multimerin 2 0.69 0.02 1.34
107 33 trm|Q9UD19 Intron-containing kallikrein 0.73 0.02 1.30
108 4 spt|P07195 L-lactate dehydrogenase B chain 0.75 0.00 1.16
109 9 spt|P08185 Corticosteroid-binding globulin 3.22 0.00 1.79
110 14 trm|Q5UGI3 Ubiquitin C splice variant 1.37 0.01 1.24
111 6 pdb|1O1P D D Chain D, Deoxy Hemoglobin 0.55 0.00 1.32
112 7 spt|P80723 Brain acid soluble protein 1 2.24 0.00 1.46
113 7 spt|P19320 Vascular cell adhesion protein 1 1.25 0.03 1.23
114 6 spt|P27797 Calreticulin 1.39 0.00 1.13
115 10 spt|Q01459 Di-N-acetylchitobiase 1.43 0.01 1.26
116 6 trm|Q6PN97 Alpha 2 macroglobulin 3.04 0.00 1.84
117 5 gb|AAV40827.1 superoxide dismutase 3 0.48 0.00 1.15
118 3 spt|P08473 Neprilysin 2.26 0.00 1.51
119 61 trm|Q9Y5Y7 LYVE-1 1.63 0.00 1.03
120 2 spt|P26038 Moesin 1.56 0.00 1.18
121 9 trm|Q6PIJ0 FCGR3A protein 0.77 0.00 1.06
122 7 spt|P14209 T cell surface glycoprotein E2 2.02 0.02 1.61
123 6 spt|P02765 Alpha-2-HS-glycoprotein 1.69 0.00 1.20
124 215 pir|A23746 Ig kappa chain V-III 1.31 0.00 1.14
125 3 trm|Q9NT71 Hypothetical protein DKFZp761A051 0.74 0.03 1.31
126 6 trm|Q9Y4W4 Type XV collagen 0.52 0.00 1.25
127 5 cra|hCP42501.1 Complement component 1 0.74 0.00 1.20
128 11 spt|P09564 T-cell antigen CD7 0.67 0.01 1.26
129 6 dbj|BAA86053.1 Carboxypeptidase E 0.79 0.02 1.20
130 6 spt|P15151 Poliovirus receptor 1.46 0.01 1.51
131 13 trm|Q8IUP2 Protocadherin 1, isoform 1 0.49 0.02 1.75
132 3 trm|Q8NBK0 Hypothetical protein 1.31 0.01 1.19
133 5 spt|P22891 Vitamin K-dependent protein Z 0.76 0.01 1.21
134 6 trm|Q9UNF4 Hyaluronic acid receptor 1.50 0.01 1.29
135 11 trm|Q9HCU0 Tumor endothelial marker 1 0.46 0.00 1.36
136 8 spt|P35527 Keratin, type I cytoskeletal 9 0.55 0.00 1.29
137 3 spt|P55285 Cadherin-6 0.41 0.00 1.39
138 3 trm|Q9BYH7 Scavenger receptor with C-type lectin type I 1.39 0.01 1.23
139 2 trm|Q13942 Calmodulin 2.64 0.00 1.39
140 8 spt|P04004 Vitronectin 1.87 0.00 1.42
141 11 trm|Q86Z23 Hypothetical protein 2.11 0.01 1.49
142 140 trm|Q9NWE3 Hypothetical protein FLJ10084 1.55 0.00 1.04
143 99 trm|Q9NWE3 Hypothetical protein FLJ10084 1.53 0.00 1.06
144 11 spt|P05109 Calgranulin A 0.42 0.00 1.34
145 58 trm|Q9NWE3 Hypothetical protein FLJ10084 1.50 0.00 1.08
146 3 trm|Q9BYH7 Scavenger receptor with C-type lectin type I 1.65 0.00 1.24
147 4 gb|AAA52018.1 Chromogranin A 0.52 0.00 1.26
148 4 emb|CAI20248.1 PPGB 1.51 0.00 1.24
149 92 pir|S12443 Ig lambda chain (Ke+O−)−human 1.35 0.03 1.24
150 7 trm|Q5TEQ5 OTTHUMP00000044363 0.29 0.00 1.58Experimental Diabetes Research 29
Table 5: Continued.
N Unique peptidesa Accession numberb Protein name Ratioc MA:NA Pvald MA:NA EFe MA:NA
151 18 trm|Q6UX86 GPPS559 2.08 0.01 1.60
152 2 trm|Q8TCZ2 MIC2L1 0.80 0.01 1.16
153 5 spt|P61970 Nuclear transport factor 2 0.78 0.01 1.18
154 284 pdb|1T04 C Anti-ifn-gamma fab in C2 space group 1.45 0.02 1.28
155 8 spt|P00790 Pepsin A 0.80 0.00 1.15
156 2 cra|hCP1778903.1 CD7 antigen 0.48 0.00 1.03
157 5 trm|O00480 Butyrophilin, subfamily 2 0.68 0.00 1.12
158 5 trm|O43653 Prostate stem cell A 1.70 0.00 1.25
159 4 trm|Q9BX83 Hemoglobin alpha 1 globin chain 0.67 0.05 1.47
160 9 spt|P11684 Uteroglobin 3.16 0.00 1.86
161 7 trm|Q7LDY7 Alpha-KG-E2 1.47 0.00 1.17
162 3 trm|Q9BYH7 Scavenger receptor 1.92 0.00 1.25
163 4 trm|Q6AZK5 KRT13 protein 0.56 0.02 1.58
164 5 spt|P09619 PDGF-R-beta 0.66 0.01 1.29
165 5 pdb|5TTR H Leu 55 Pro Transthyretin 1.46 0.02 1.33
166 3 rf|NP 877418.1 Mucin 1, transmembrane 0.49 0.02 1.78
167 2 trm|Q5SWW9 OTTHUMP00000060590 0.39 0.01 1.76
168 2 rf|NP 003217.2 Trefoil factor 3 1.63 0.00 1.22
169 3 spt|Q99574 Neuroserpin 0.63 0.01 1.36
170 21 trm|Q9Y3U9 Hypothetical protein DKFZp566C243 0.75 0.00 1.06
171 23 gb|AAB27607.1 Prostaglandin D synthase 1.20 0.00 1.10
172 4 gb|AAO11857.1 Immunoglobulin 1.38 0.00 1.14
173 2 trm|Q5VTA6 Cubilin 0.79 0.03 1.23
174 3 trm|Q5SY67 OTTHUMP00000059857 0.69 0.02 1.33
175 54 spt|P15814 Immunoglobulin lambda-like polypeptide 1 2.50 0.01 1.37
176 2 spt|P22352 Plasma glutathione peroxidase 0.70 0.00 1.13
177 7 gb|AAL68978.1 Mutant beta globin 0.32 0.00 1.77
178 6 spt|P35908 KCytokeratin 2e 0.50 0.03 1.74
179 284 dbj|BAB18261.1 Anti-HBs antibody light chain 3.19 0.00 1.53
180 3 rf|XP 370615.2 Hypothetical protein 0.53 0.03 1.72
181 164 gb|AAB50880.2 Anitubulin IgG1 kappa VL chain 1.64 0.00 1.30
182 170 dbj|BAC01692.1 Immunoglobulin kappa light chain 2.49 0.01 1.79
183 2 trm|Q7RTN9 Type II keratin K6h 0.43 0.01 1.52
184 3 spt|P21926 Motility-related protein 1.70 0.03 1.45
185 2 spt|Q13873 Bone morphogenetic protein receptor 0.61 0.01 1.08
186 4 gb|AAA62175.1 Heat shock protein 27 0.53 0.00 1.38
187 15 spt|P02787 transferrin 1.86 0.00 1.25
188 2 spt|P07108 Acyl-CoA-binding protein 2.20 0.02 1.47
189 2 spt|Q9NZH0 G protein-coupled receptor family C 1.27 0.04 1.25
190 2 trm|Q96E46 Fructose-1,6-bisphosphatase 1 0.44 0.00 1.01
191 44 gb|AAB53267.1 Immunoglobulin V-region light chain 1.40 0.03 1.30
192 8 gb|AAR32503.1 Immunoglobulin heavy chain 0.46 0.00 1.19
193 7 rf|NP 653247.1 Immunoglobulin J chain 0.37 0.01 1.88
194 29 emb|CAA12585.1 Ig heavy chain variable region 1.50 0.00 1.13
195 4 gb|AAD16731.1 Immunoglobulin lambda light chain 1.58 0.00 1.11
196 33 trm|Q6UXB8 HGSC289 (OTTHUMP00000039678) 1.27 0.04 1.22
aThe numbers of unique peptides and MS/MS spectrum observed by ProteinPilot software were determined only for those peptides with ≥95% conﬁdence.
bAccessionnumbersrepresententriesintheHumanCDSdatabase(humanKBMS5.0,2005-03-02;atotalof187,748entriesprovidedbyAppliedBiosystems).
c−eThe iTRAQ ratio, P value, and EF value in microalbumiuric versus normoalbuminuric urine, respectively.30 Experimental Diabetes Research
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